2Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.N Engl J Med, 2001, 344: 68-69.
3Ng HJ, Lim LC. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol, 2001, 80: 549-552.
4Silvestri F, Ermacora A, Sperotto A, et al. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol, 2000, 108: 394-396.
5Liaw Y F, Leung N, Guan R, et al. Asian- Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 2003,18(3): 239-245.
6Fung S K, Lok A S. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection. Hepatology, 2004,40 (4): 790-792.
7Janssen H L A, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet,2005,365(9454): 123-129.
8Santantonio T, Mazola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol,2000,32(2): 300-306.
9Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology,2000,31(1): 207-210.
10Liaw YF, Sung JJY, Chow WE, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med,2004,351 (12):1521-1531.
9Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
